Tvardi Therapeutics, Inc. Common Stock TVRD
Key Stats
- Today's Range
- $1.85 – $1.94
- 50-Day Range
- $1.50 – $5.69
- 52-Week Range
- $1.50 – $43.65
- Volume
- 104K shs
- Average Volume
- 4.78 million shs
- Market Cap
- $23.36 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.10%
- Days to Cover
- 1.00
About Tvardi Therapeutics, Inc. Common Stock
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Related Stocks
Compare head-to-head: TVRD vs LLY·TVRD vs JNJ·TVRD vs ABBV·TVRD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.